Core Insights - Soleno Therapeutics is presenting data on its DCCR clinical development program for Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology Meeting in November 2024 [1] Group 1: Clinical Presentations - The first oral presentation will discuss the relaxation of food control parameters based on improvements in the Food Safe Zone Questionnaire with a reduction of hyperphagia in clinical trials of DCCR in PWS participants, scheduled for November 17, 2024 [2] - The second oral presentation will cover long-term efficacy results of DCCR tablets in PWS participants from completed studies, set for November 18, 2024 [2] Group 2: Prader-Willi Syndrome Overview - PWS occurs in approximately 1 in every 15,000 live births, characterized by hyperphagia, which can severely impact quality of life and lead to significant mortality risks [3] - Other symptoms of PWS include behavioral issues, cognitive disabilities, low muscle tone, and developmental delays, with no approved therapies currently available to address these aspects [3] Group 3: DCCR (Diazoxide Choline) Details - DCCR is a proprietary extended-release formulation of diazoxide choline, administered once daily, and has shown promise in addressing hyperphagia and other symptoms in PWS [4] - The DCCR development program is backed by data from multiple completed Phase 1 and Phase 2 clinical studies, including one specifically in PWS [4] Group 4: Company Overview - Soleno Therapeutics is focused on developing and commercializing novel therapeutics for rare diseases, with an NDA for DCCR currently under FDA review and granted Priority Review status [5]
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024